

Pascaline Boudou-rouquette

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4722472/publications.pdf>

Version: 2024-02-01

119
papers

3,125
citations

249298

26
h-index

190340

53
g-index

127
all docs

127
docs citations

127
times ranked

4889
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group. <i>International Journal of Cancer</i> , 2022, 150, 645-653.	2.3	9
2	Predicting Frailty and Geriatric Interventions in Older Cancer Patients: Performance of Two Screening Tools for Seven Frailty Definitionsâ€”ELCAPA Cohort. <i>Cancers</i> , 2022, 14, 244.	1.7	8
3	Lack of Prognostic Value of <i>CTNNB1</i> Mutation Profile in Desmoid-Type Fibromatosis. <i>Clinical Cancer Research</i> , 2022, 28, 4105-4111.	3.2	11
4	Energy expenditure profiles and the risk of early limiting toxicity in older patients with cancer: The ELCAPA-25 prospective cohort survey. <i>Clinical Nutrition</i> , 2022, 41, 1073-1082.	2.3	6
5	Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2762-2770.	3.2	10
6	Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients. <i>Pharmaceutics</i> , 2022, 14, 1224.	2.0	3
7	Health literacy in patients with cancer: A multicenter national study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6541-6541.	0.8	0
8	A decision curve analysis of the clinical usefulness of a two-step frailty assessment strategy in older patients with prostate, breast, colorectal, or lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12011-12011.	0.8	1
9	Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab. <i>Cancers</i> , 2022, 14, 3214.	1.7	2
10	REGOMAIN: A randomized, placebo-controlled, double-blinded, multicenter, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients (pts) with high-grade bone sarcomas (HGBS) at diagnosis or relapse and without complete remission after standard treatment.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS11585-TPS11585.	0.8	0
11	Postoperative Outcome of Surgery with Pancreatic Resection for Retroperitoneal Soft Tissue Sarcoma: Results of a Retrospective Bicentric Analysis on 50 Consecutive Patients. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2299-2306.	0.9	9
12	High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSÃ© pembrolizumab study from Unicancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11520-11520.	0.8	19
13	Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. <i>European Journal of Cancer</i> , 2021, 150, 108-118.	1.3	16
14	Prevalence of drugâ€”drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 741-751.	1.1	4
15	Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in Paris. <i>Clinical Medicine</i> , 2021, 21, e552-e555.	0.8	1
16	Prevalence and prognostic impact of cachexia among older patients with cancer: a nationwide crossâ€”sectional survey (NutriAgeCancer). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1477-1488.	2.9	43
17	Rare bone sarcomas: a retrospective analysis of 145 adult patients from the French Sarcoma Group. <i>International Journal of Cancer</i> , 2021, , .	2.3	0
18	Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study. <i>EBioMedicine</i> , 2021, 73, 103630.	2.7	6

#	ARTICLE	IF	CITATIONS
19	Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options. <i>Journal of Medical Genetics</i> , 2020, 57, 104-108.	1.5	16
20	Potential drug-drug interactions and risk of unplanned hospitalization in older patients with cancer: A survey of the prospective ELCAPA (ELderly CANcer PATients) cohort. <i>Journal of Geriatric Oncology</i> , 2020, 11, 586-592.	0.5	22
21	Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients. <i>Clinical Nutrition</i> , 2020, 39, 1893-1899.	2.3	16
22	The impact of body composition parameters on severe toxicity of nivolumab. <i>European Journal of Cancer</i> , 2020, 124, 170-177.	1.3	32
23	Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 497-505.	1.1	7
24	First referral to an integrated onco-palliative care program: a retrospective analysis of its timing. <i>BMC Palliative Care</i> , 2020, 19, 31.	0.8	11
25	Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. <i>Clinical Therapeutics</i> , 2020, 42, 1302-1316.	1.1	13
26	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. <i>Cancers</i> , 2020, 12, 473.	1.7	72
27	Diffuse large B-cell lymphoma after nivolumab treatment for lung cancer: A case report and a World Health Organization pharmacovigilance database review. <i>European Journal of Cancer</i> , 2020, 130, 20-22.	1.3	1
28	A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line treatment to patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS): Final results of the LMS-02 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11506-11506.	0.8	0
29	Higher complications after previous external beam radiation for extremity soft-tissue sarcoma in the surgical treatment of a local recurrence: a comparative retrospective study of one hundred and three patients. <i>International Orthopaedics</i> , 2019, 43, 727-733.	0.9	3
30	Lack of efficacy of neoadjuvant chemotherapy in adult patients with maxillo-facial high-grade osteosarcomas: A French experience in two reference centers. <i>Oral Oncology</i> , 2019, 95, 79-86.	0.8	15
31	The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. <i>Journal of Translational Medicine</i> , 2019, 17, 357.	1.8	88
32	Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2019, 11, 762.	1.7	5
33	Depressive Symptom Profiles and Survival in Older Patients with Cancer: Latent Class Analysis of the ELCAPA Cohort Study. <i>Oncologist</i> , 2019, 24, e458-e466.	1.9	15
34	Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?. <i>Cancers</i> , 2019, 11, 1784.	1.7	28
35	How to Optimize Cancer Treatment in Older Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 109-116.	0.6	16
36	Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 120-133.	5.1	222

#	ARTICLE	IF	CITATIONS
37	Metabolic profile and neoadjuvant chemotherapy sensitivity in high-grade bone sarcoma.. Journal of Clinical Oncology, 2019, 37, e22506-e22506.	0.8	0
38	Abstract 4107: Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab efficacy in advanced non-small cell lung cancer. , 2019, , .		0
39	Abstract 4955: Impact of PD-1, PD-L1 and EB13 on prognosis in a cohort of localized high grade undifferentiated pleomorphic sarcoma patients. , 2019, , .		0
40	Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 928-940.	2.5	62
41	Resting energy expenditure in the risk assessment of anticancer treatments. Clinical Nutrition, 2018, 37, 558-565.	2.3	25
42	Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. Fundamental and Clinical Pharmacology, 2018, 32, 98-107.	1.0	22
43	<i>TP53, STK11</i>, and <i>EGFR</i> Mutations Predict Tumor Immune Profile and the Response to Anti-“PD-1 in Lung Adenocarcinoma. Clinical Cancer Research, 2018, 24, 5710-5723.	3.2	257
44	Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients. Journal of Pharmaceutical and Biomedical Analysis, 2018, 158, 174-183.	1.4	50
45	BRCA2 Loss-of-Function and High Sensitivity to Cisplatin-Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine. American Journal of the Medical Sciences, 2018, 356, 404-407.	0.4	5
46	Abstract 4546: The tumor inflammation signature is predictive of anti-PD1 treatment benefit in the CERTIM pan-cancer cohort. Cancer Research, 2018, 78, 4546-4546.	0.4	2
47	Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer.. Journal of Clinical Oncology, 2018, 36, 11504-11504.	0.8	6
48	Outcome of 91 clear cell sarcoma tumor patients: A retrospective study from the French Sarcoma Group (GSF-GETO).. Journal of Clinical Oncology, 2018, 36, 11552-11552.	0.8	2
49	Clinical and pharmacological parameters associated with nivolumab toxicity.. Journal of Clinical Oncology, 2018, 36, 3066-3066.	0.8	0
50	Rare bone sarcoma: A retrospective analysis of 149 adult patients from the French Sarcoma Group.. Journal of Clinical Oncology, 2018, 36, 11523-11523.	0.8	0
51	Specific needs of non-visceral sarcoma patients: Evidence from an early multidisciplinary intervention.. Journal of Clinical Oncology, 2018, 36, e22133-e22133.	0.8	0
52	Abstract 1693: Prediction of the efficacy of nivolumab using resting energy expenditure in metastatic non-small cell lung cancer (mNSCLC) patients. , 2018, , .		0
53	Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients. Journal of Pharmaceutical and Biomedical Analysis, 2017, 139, 30-36.	1.4	35
54	Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France. Cancer Chemotherapy and Pharmacology, 2017, 79, 1051-1055.	1.1	14

#	ARTICLE	IF	CITATIONS
55	Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. <i>Investigational New Drugs</i> , 2017, 35, 436-441.	1.2	73
56	Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy. <i>American Journal of Clinical Nutrition</i> , 2017, 105, 1139-1147.	2.2	74
57	Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. <i>European Journal of Cancer</i> , 2017, 83, 125-131.	1.3	134
58	Pharmacokinetics and pharmacodynamics of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma. <i>International Journal of Pharmacokinetics</i> , 2017, 2, 257-283.	0.5	1
59	Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old. <i>Investigational New Drugs</i> , 2017, 35, 242-246.	1.2	20
60	Individualized Pazopanib Dosing Letter. <i>Clinical Cancer Research</i> , 2017, 23, 6377-6377.	3.2	3
61	Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. <i>Oncotarget</i> , 2017, 8, 21903-21917.	0.8	140
62	Pituitary Lesion of Unknown Origin: Think Epithelioid Angiosarcoma. <i>Journal of the Endocrine Society</i> , 2017, 1, 72-74.	0.1	0
63	Predictive and prognostic value of systemic inflammatory response biomarkers in patients receiving nivolumab for metastatic non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2017, 35, 3055-3055.	0.8	7
64	Effect of nivolumab therapy on pulmonary artery. <i>Journal of Clinical Oncology</i> , 2017, 35, e18266-e18266.	0.8	1
65	Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers. <i>Oncotarget</i> , 2017, 8, 34245-34257.	0.8	13
66	Prognosis of desmoid tumors (DT): A prospective nationwide survey of 771 patients (pts). <i>Journal of Clinical Oncology</i> , 2017, 35, 11047-11047.	0.8	0
67	Early TKI-pharmokinetics and circulating tumor DNA (ctDNA) to predict outcome in patients with EGFR-mutated non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2017, 35, 11544-11544.	0.8	1
68	Association of muscle mass with pathologic response and toxicity in localized bladder cancer patients treated by neoadjuvant chemotherapy (NAC) and radical cystectomy (RC). <i>Journal of Clinical Oncology</i> , 2017, 35, e16022-e16022.	0.8	0
69	Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1433-1444.	1.5	19
70	Evaluation of the interindividual variability in plasma nivolumab level in non-small-lung cancer outpatients: preliminary results. <i>Annals of Oncology</i> , 2016, 27, vi530.	0.6	3
71	A Real-Life Experience of Bevacizumab in Elderly Women With Advanced Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1196-1200.	1.2	7
72	Evaluation of baseline asymptomatic dysimmunity prevalence in cancer patients receiving monoclonal anti-PD1 antibodies. <i>Journal of Clinical Oncology</i> , 2016, 34, e14551-e14551.	0.8	1

#	ARTICLE	IF	CITATIONS
73	A multidisciplinary team dedicated to the management of patients treated with PD1 inhibitors: The Cochon hospital experience.. Journal of Clinical Oncology, 2016, 34, e18208-e18208.	0.8	0
74	Integration of Oncology and Palliative Care, a Forgotten Indicator: Shared Decisionâ€Making. Oncologist, 2015, 20, e26.	1.9	9
75	Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics. Expert Opinion on Investigational Drugs, 2015, 24, 673-687.	1.9	7
76	Sorafenib for patients with differentiated thyroid cancer. Lancet, The, 2015, 385, 227-228.	6.3	8
77	Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. Investigational New Drugs, 2015, 33, 257-268.	1.2	47
78	Lâ€™information sur le pronosticÂ: quel sens pour les patientsÂ?. Medecine Palliative, 2015, 14, 98-110.	0.0	0
79	Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 785-794.	1.5	31
80	Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters. Cancer Chemotherapy and Pharmacology, 2015, 76, 1033-1039.	1.1	7
81	Soluble VEGFRâ€1: A new biomarker of sorafenibâ€related hypertension. Journal of Clinical Pharmacology, 2015, 55, 478-479.	1.0	3
82	Risk assessment of anticancer treatments beyond performance status: A prospective study in 277 cancer patients.. Journal of Clinical Oncology, 2015, 33, 9620-9620.	0.8	1
83	Pegylated liposomal doxorubicin-induced palmar plantar erythrodyesthesia: Identification of risks factors.. Journal of Clinical Oncology, 2015, 33, e13569-e13569.	0.8	0
84	Is standard dose appropriate in elderly non-small cell lung carcinoma (NSCLC) patients treated with erlotinib?. Journal of Clinical Oncology, 2015, 33, 9537-9537.	0.8	0
85	Identification of candidates for sorafenib dose-escalation using sorafenib plasmatic concentration monitoring: Proof of concept.. Journal of Clinical Oncology, 2015, 33, 2572-2572.	0.8	0
86	How should we manage bevacizumab toxicity in lung cancer patients?. Lung Cancer Management, 2014, 3, 355-363.	1.5	0
87	Sorafenib in Thyroid Cancer Patients: Learning From Toxicity. Oncologist, 2014, 19, e3.	1.9	5
88	Drug interactions with solid tumour-targeted therapies. Critical Reviews in Oncology/Hematology, 2014, 89, 179-196.	2.0	85
89	Fractionation of daily dose increases the predicted risk of severe sorafenib-induced handâ€foot syndrome (HFS). Cancer Chemotherapy and Pharmacology, 2014, 73, 287-297.	1.1	12
90	Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients. Expert Opinion on Drug Safety, 2014, 13, 663-673.	1.0	15

#	ARTICLE	IF	CITATIONS
91	Multidisciplinary risk assessment to reveal cancer treatments in complex cancer patients.. Journal of Clinical Oncology, 2014, 32, 170-170.	0.8	1
92	Multidisciplinary risk assessment to reveal cancer treatments in unfit cancer patients.. Journal of Clinical Oncology, 2014, 32, 9551-9551.	0.8	0
93	Association of sunitinib exposure with toxicity outcome in a real-life population of elderly patients with cancer.. Journal of Clinical Oncology, 2014, 32, e20523-e20523.	0.8	0
94	An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 928, 93-97.	1.2	35
95	Nutritional Status Is Superior to the ECOG Performance Status in Predicting the Dose-Intensity of the GEMOX Chemotherapy Regimen in Patients with Advanced Cancer. Nutrition and Cancer, 2013, 65, 1254-1257.	0.9	5
96	Feasibility of Gemcitabine plus Oxaliplatin in Advanced Hepatocellular Carcinoma Patients with Child-Pugh B Cirrhosis. Oncology, 2013, 84, 32-38.	0.9	22
97	Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. British Journal of Cancer, 2013, 108, 1034-1041.	2.9	204
98	Cervical extravasation of bevacizumab. Anti-Cancer Drugs, 2013, 24, 426-428.	0.7	5
99	How to predict sunitinib exposure and toxicity: A pharmacokinetic-pharmacodynamic study.. Journal of Clinical Oncology, 2013, 31, e15592-e15592.	0.8	1
100	Arterial stiffness to predict hypertensive response to antiangiogenic drugs.. Journal of Clinical Oncology, 2013, 31, e13589-e13589.	0.8	0
101	Cost Effectiveness of Integrated Medicine in Patients With Cancer Receiving Anticancer Chemotherapy. Journal of Oncology Practice, 2012, 8, 205-210.	2.5	20
102	Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications. Annals of Oncology, 2012, 23, 280-281.	0.6	38
103	Variability of Sorafenib Toxicity and Exposure over Time: A Pharmacokinetic/Pharmacodynamic Analysis. Oncologist, 2012, 17, 1204-1212.	1.9	91
104	Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma. Anti-Cancer Drugs, 2012, 23, 745-748.	0.7	16
105	Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2. Anti-Cancer Drugs, 2012, 23, 739-744.	0.7	18
106	Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer. Lung Cancer, 2012, 77, 104-109.	0.9	16
107	Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Investigational New Drugs, 2012, 30, 2046-2049.	1.2	95
108	Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study. Supportive Care in Cancer, 2012, 20, 2235-2239.	1.0	8

#	ARTICLE	IF	CITATIONS
109	Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. <i>Medical Oncology</i> , 2012, 29, 2793-2799.	1.2	40
110	Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGT1A9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study. <i>PLoS ONE</i> , 2012, 7, e42875.	1.1	88
111	Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients. <i>Investigational New Drugs</i> , 2012, 30, 1756-1760.	1.2	9
112	Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2012, 7, e37563.	1.1	252
113	Sarcoligo: Impact of local ablative treatment of oligometastatic sarcomas on overall survival.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10042-10042.	0.8	0
114	Targeted Therapy in CMML: Complete Molecular Response to Sorafenib in a Patient with a FLT3-ITD Malignant Hematopoiesis. <i>Blood</i> , 2012, 120, 4786-4786.	0.6	0
115	Functional and Clinical Evidence of the Influence of Sorafenib Binding to Albumin on Sorafenib Disposition in Adult Cancer Patients. <i>Pharmaceutical Research</i> , 2011, 28, 3199-3207.	1.7	36
116	Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. <i>Targeted Oncology</i> , 2011, 6, 253-258.	1.7	117
117	Imprint cytology in tumor tissue bank quality control: an efficient method to evaluate tumor necrosis and to detect samples without tumor cells. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 456, 443-447.	1.4	11
118	Reply to Bone morphogenetic proteins and zoledronic acid. <i>Annals of Oncology</i> , 2009, 20, 2019.	0.6	0
119	Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. <i>Annals of Oncology</i> , 2008, 19, 1975.	0.6	26